OCT imaging company NinePoint Medical names new president/CEO

Optical coherence tomography (OCT) imaging device maker NinePoint Medical (Bedford, MA) has appointed Eman Namati, Ph.D., to president and chief executive officer, succeeding Christopher von Jako, Ph.D., who will continue to serve on the Board of Directors as an independent member. Namati will assume day-to-day leadership at the company while working in collaboration with Merit Medical Systems (South Jordan, UT), which now manages the sales distribution and customer service for NinePoint Medical's NvisionVLE Imaging System.

Related: NinePoint Medical, Merit Medical Systems enter OCT imaging partnership

Eman joined NinePoint Medical during its inception in 2010 as a technical co-founder and has served as the company's vice president of research and development for the past four years. He has overseen the development of highly complex imaging systems and single-use devices from concept through commercialization, including translation of the original academic prototype into the NvisionVLE platform as well as the recently launched Real-time Targeting laser marking system. Prior to his time at NinePoint, Namati was a researcher developing optical imaging systems at Massachusetts General Hospital (Boston, MA). He worked with Professors Guillermo Tearney, MD, Ph.D., and Brett Bouma, Ph.D. on the OCT technology that was licensed to NinePoint Medical. Namati holds a Ph.D. in Biomedical Engineering and a double undergraduate degree in Engineering (BE) and Science (BSc) from Flinders University Australia.

The NvisionVLE Imaging System provides a high-resolution, real-time scan of the esophagus using OCT, which uses infrared light to view structures not evident with conventional imaging (such as ultrasound), to potentially identify disease that would have otherwise been missed. With the recent addition of a Real-time Targeting feature, physicians can locate and mark areas of interest to enable more accurate targeting, potentially leading to improved diagnosis and more effective therapeutic decisions for patients.

For more information, please visit www.ninepointmedical.com.